FRAMINGHAM, MA -- (MARKET WIRE) -- September 27, 2006 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced that it intends to seek regulatory guidance for IoGen™ in Europe. The Company will request regulatory guidance meetings with the regulatory authorities in the United Kingdom, Germany and Holland. The purpose of these meetings is to clarify what additional data, if any, will be required before Symbollon submits IoGen for marketing approval in those countries as a treatment for moderate to severe cyclic breast pain and tenderness associated with fibrocystic breast. Symbollon anticipates such meetings to be held later this year.
